Bookmark and Share

ACOMPLIA Drug Information Page

Updated 11/08/2010 12:12:41 AM

ProductSourceDateLinkData
ACOMPLIAMHRA2008-11-6ACOMPLIA-MHRA-2008-11-6MHRA has issued drug updates: Varenicline: adverse psychiatric reactions, including depression Tigecycline: new formulation affects compatibility Ezetimibe and possible increased risk of cancer: results of SEAS study Rimonabant: European suspension of marketing authorisation Inhaled anticholinergics: recent published data for risk of death or stroke Paracetamol use in infancy: no strong evidence for asthma link
ACOMPLIAMHRA2008-5-6ACOMPLIA-MHRA-2008-5-6MHRA has issued drug updates: Rimonabant (Acomplia): depression; psychiatric adverse reactions Exenatide (Byetta): risk of acute pancreatitis Monitoring the safety of antiretroviral drugs Abacavir and didanosine: results of D:A:D study Enoxaparin (Clexane) contamination: advice for healthcare professionals
ACOMPLIAMHRA2007-8-1ACOMPLIA-MHRA-2007-8-1MHRA has issued drug updates: Gadolinium-containing contrast agents and nephrogenic systemic fibrosis Extraneal and products that contain (or are metabolised to) maltose, xylose, or galactose: false glucose reading a1-adrenoreceptor antagonists and intraoperative floppy iris syndrome Cabergoline: risk of cardiovalvulopathy Linezolid: restriction of indication Dopamine agonists and pathological gambling, increased libido, and hypersexuality Antidepressants and risk of suicidal behaviour Isotretinoin for severe acne Smoking-cessation aids

Joining this website will allow you to recieve emails about any pharmaceutial you are interested in or you can search for other pharmaceuticals on this website. Joining should only take 2 minutes.



Image of checkdrugs.com Logo
© Cardan Technologies Inc

This site is presented as an educational source only and you use it at your own risk. The information on this site is not a substitute for a visit with your doctor or pharmacist. Always talk to your doctor before changing medications or dosage, or if you experience any serious side effects.